Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential ADC therapy after CDK4/6 inhibitor progression in HR+/HER2- advanced breast cancer
ChiCTR2500106726Phase 4Not yet recruiting
- Sponsor
- Xi'an International Medical Center Hospital
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer (2 cohorts), sponsored by Xi'an International Medical Center Hospital. Primary endpoint: Progression-free survival 1 (PFS1). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecansacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500106726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106726.